EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The cervico‐vaginal DNA methylation WID ‐ qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer

Elisa Redl iD, Chiara Herzog iD, Charlotte Vavourakis iD, James Barrett iD, Allison Jones, Iona Evans, Daniel Reisel, Ranjit Manchanda, Line Bjørge, Michal Zikan, David Cibula, Twana Alkasalias und 7 weitere

International Journal of Cancer · 15.05.2026 · 158 (10) · 2530-2536

DOI: 10.1002/ijc.70354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 29.01.2026. Verfasst von Elisa Redl und 18 weiteren Autor:innen. Beteiligte Einrichtung: European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Hall in Tirol, Austria. Hauptthemen laut MEDLINE: DNA Methylation, Ovarian Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Eve Appeal, Land Tirol, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA methylation‐based WID‐qEC test, applied to cervico‐vaginal samples, has been validated for the accurate detection of endometrial and cervical cancers. However, a small proportion of women test positive despite the absence of these cancers. The aim of this study was to explore the biological and clinical characteristics associated with such WID‐qEC‐positive cases to inform potential follow‐up strategies. We analyzed 1269 cervico‐vaginal samples from women without endometrial or cervical cancer, including healthy controls ( n = 624), women with benign gynecological conditions ( n = 324), and ovarian cancer cases ( n = 321). Of the 80 WID‐qEC‐positive results, 43 (54%) were from women with ovarian cancer. WID‐qEC positivity was associated with the presence of ovarian cancer (adjusted odds ratio [OR] 2.93; 95% CI 1.75–4.95) and with a higher number of lifetime ovulatory cycles (adjusted OR 2.67; 95% CI 1.06–7.50), a known ovarian cancer risk factor. Both associations were independent of age, menopausal status, hormone replacement therapy usage, or family history of breast or ovarian cancer. Our findings suggest that in the absence of endometrial or cervical cancer, WID‐qEC positivity may indicate an elevated risk or presence of ovarian cancer. While the standalone positive predictive value (PPV) for ovarian cancer detection remains low in the general population, we outline how WID‐qEC could be used in a two‐step triage approach. In women presenting with abnormal bleeding, combining WID‐qEC positivity with a highly specific plasma‐based cell‐free DNA methylation test (e.g., with 60%–80% sensitivity and ~98.4% specificity) could theoretically yield a PPV of around 30%–40%. This hypothetical modeling is intended solely to illustrate how WID‐qEC positivity might inform future triage research, rather than to propose a clinical diagnostic algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationOvarian NeoplasmsBiomarkers, TumorHumansFemaleMiddle AgedUterine Cervical NeoplasmsEndometrial NeoplasmsAdultEpigenesis, GeneticCase-Control StudiesVaginaAgedCervix Uteri

Stichwörter der Autor:innen

DNA methylationcervico‐vaginal sample; WID‐qEC testovarian cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Hall in Tirol, Austria.
  • Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
  • Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
  • Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK.
  • Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Department of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK.

ORCID-Profile: Elisa Redl, Chiara Herzog, Charlotte Vavourakis, James Barrett, Louis Dubeau, Martin Widschwendter

Förderung

  • The Eve Appeal
  • Land Tirol
  • Horizon 2020 Framework Programme
  • Standortagentur Tirol
  • European Research Council

Zitieren

APA

Redl, E., Herzog, C., Vavourakis, C., Barrett, J., Jones, A., Evans, I., Reisel, D., Manchanda, R., Bjørge, L., Zikan, M., Cibula, D., Alkasalias, T., Rådestad, A. F., Gemzell-Danielsson, K., Dubeau, L., MacDonald, N., Jurkovic, D., Pashayan, N., & Widschwendter, M. (2026). The cervico‐vaginal DNA methylation WID ‐ qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. International Journal of Cancer, 158(10), 2530-2536. https://doi.org/10.1002/ijc.70354

Vancouver

Redl E, Herzog C, Vavourakis C, Barrett J, Jones A, Evans I, et al. The cervico‐vaginal DNA methylation WID ‐ qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. International Journal of Cancer. 2026;158(10):2530-2536. doi:10.1002/ijc.70354

BibTeX
@article{Redl2026,
  author = {Redl, Elisa and Herzog, Chiara and Vavourakis, Charlotte and Barrett, James and Jones, Allison and Evans, Iona and Reisel, Daniel and Manchanda, Ranjit and Bjørge, Line and Zikan, Michal and Cibula, David and Alkasalias, Twana and Rådestad, Angelique Flöter and Gemzell-Danielsson, Kristina and Dubeau, Louis and MacDonald, Nicola and Jurkovic, Davor and Pashayan, Nora and Widschwendter, Martin},
  title = {The cervico‐vaginal DNA methylation WID ‐ qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {10},
  pages = {2530--2536},
  doi = {10.1002/ijc.70354}
}
Kostenlos starten →